Cytokinetics, Incorporated has a 1-year low of $34.19 and a 1-year high of $75.71. Cytokinetics ( NASDAQ:CYTK – Get Free Report ) last released its earnings results on Thursday, February 27th.

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

A biotech in­cu­bat­ed by RA Cap­i­tal has se­cured a $57.5 mil­lion Se­ries B to be­gin a mid-stage tri­al for its car­dio drug this quar­ter and … ...

At close: April 9 at 4:00:03 PM EDT ...

At close: April 11 at 4:00:01 PM EDT ...